Spotlight on HS With Dr. Martina Porter
Martina Porter, MD, takes a deep dive into new four-year data on continuous treatment with secukinumab (Cosentyx, Novartis) in patients with hidradenitis suppurativa (HS).
Day: November 7, 2025
Martina Porter, MD, takes a deep dive into new four-year data on continuous treatment with secukinumab (Cosentyx, Novartis) in patients with hidradenitis suppurativa (HS).